Literature DB >> 32000099

Who is willing to participate in research? A screening model for an anxiety and depression trial in the epilepsy clinic.

Heidi M Munger Clary1, Rachel D Croxton2, Jonathan Allan3, James Lovato4, Gretchen Brenes5, Beverly M Snively6, Mingyu Wan7, James Kimball8, Matthew H Wong9, Cormac A O'Donovan10, Kelly Conner11, Victor Jones9, Pamela Duncan12.   

Abstract

OBJECTIVE: Anxiety and depression in epilepsy are prevalent, associated with poor outcomes, underrecognized, undertreated, and thus a key area of need for treatment research. The objective of this study was to assess factors associated with research participation among epilepsy clinic patients who screened positive for anxiety or depression. This was accomplished by characterizing clinical and psychiatric factors among patients seen in an epilepsy clinic and evaluating which factors were associated with consent for potential research participation, via a combined clinical and research screening model.
METHODS: In a pragmatic trial of anxiety and depression treatment in epilepsy, individuals with a positive screen for anxiety and/or depression at a routine epilepsy clinic visit were invited to opt-in (via brief electronic consent) to further eligibility assessment for a randomized treatment study. Information on psychiatric symptoms and treatment characteristics were collected for dual clinical care and research screening purposes. Cross-sectional association of demographic, clinical, and psychiatric factors with opting-in to research was analyzed by multiple logistic regression.
RESULTS: Among N = 199 unique adults with a first positive screen for anxiety and/or depression among 786 total screening events, 154 (77.4%) opted-in to further potential research assessment. Higher depression scores and current treatment with an antidepressant were independently associated with opting-in to research (depression odds ratio (OR) = 1.13 per 1-point increase in Neurological Disorders Depression Inventory-Epilepsy (NDDI-E) score, p = 0.028, 95% confidence interval (CI): 1.01-1.26; antidepressant OR = 2.37, p = 0.041, CI: 1.04-5.41). Nearly half of the 199 individuals (43.7%) with anxiety and/or depression symptoms were already being treated with an antidepressant, and 46.7% were receiving neither antidepressant therapy nor mental health specialty care. One-quarter (24.1%) reported a past psychiatric hospitalization, yet only half of these individuals were receiving mental health specialty care. SIGNIFICANCE: Our results demonstrate a high willingness to participate in research using a brief electronic consent approach at a routine clinic visit. Adults with persistent anxiety or depression symptoms despite antidepressant therapy and those with higher depression scores were more willing to consider a randomized treatment study. This has implications for future study design, as individuals already on treatment or those with more severe symptoms are often excluded from traditional research designs. We also found a high burden of psychiatric disease and high prevalence of persistent symptoms despite ongoing antidepressant treatment.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety; Depression; Epilepsy; Pragmatic trial; Research participation; Treatment

Mesh:

Substances:

Year:  2020        PMID: 32000099      PMCID: PMC7282472          DOI: 10.1016/j.yebeh.2020.106907

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  29 in total

1.  Rapid detection of major depression in epilepsy: a multicentre study.

Authors:  Frank G Gilliam; John J Barry; Bruce P Hermann; Kimford J Meador; Victoria Vahle; Andres M Kanner
Journal:  Lancet Neurol       Date:  2006-05       Impact factor: 44.182

2.  Anxiety disorders in epilepsy: the forgotten psychiatric comorbidity.

Authors:  Andres M Kanner
Journal:  Epilepsy Curr       Date:  2011-05       Impact factor: 7.500

3.  The treatment of depression in patients with epilepsy. A double-blind trial.

Authors:  M M Robertson; M R Trimble
Journal:  J Affect Disord       Date:  1985-09       Impact factor: 4.839

4.  A Trial of Sertraline or Cognitive Behavior Therapy for Depression in Epilepsy.

Authors:  Frank G Gilliam; Kevin J Black; Jewell Carter; Kenneth E Freedland; Yvette I Sheline; Wei-Yann Tsai; Patrick J Lustman
Journal:  Ann Neurol       Date:  2019-08-15       Impact factor: 10.422

5.  Seizure frequency and patient-centered outcome assessment in epilepsy.

Authors:  Hyunmi Choi; Marla J Hamberger; Heidi Munger Clary; Rebecca Loeb; Frankline M Onchiri; Gus Baker; W Allen Hauser; John B Wong
Journal:  Epilepsia       Date:  2014-06-05       Impact factor: 5.864

6.  Epilepsy is associated with unmet health care needs compared to the general population despite higher health resource utilization--a Canadian population-based study.

Authors:  Aylin Y Reid; Amy Metcalfe; Scott B Patten; Samuel Wiebe; Sophie Macrodimitris; Nathalie Jetté
Journal:  Epilepsia       Date:  2012-01-05       Impact factor: 5.864

7.  Association of subjective anxiety, depression, and sleep disturbance with quality-of-life ratings in adults with epilepsy.

Authors:  Patrick Kwan; Evelyn Yu; Howan Leung; Teresa Leon; Marko A Mychaskiw
Journal:  Epilepsia       Date:  2008-12-15       Impact factor: 5.864

8.  Patterns and frequency of the treatment of depression in persons with epilepsy.

Authors:  Kirsten M Fiest; Scott B Patten; K Chelsea Altura; Andrew G M Bulloch; Colleen J Maxwell; Samuel Wiebe; Sophia Macrodimitris; Nathalie Jetté
Journal:  Epilepsy Behav       Date:  2014-09-07       Impact factor: 2.937

9.  Epilepsy care and mental health care for people with epilepsy: California Health Interview Survey, 2005.

Authors:  Alexander W Thompson; Rosemarie Kobau; Royce Park; David Grant
Journal:  Prev Chronic Dis       Date:  2012-02-23       Impact factor: 2.830

10.  Duty, desire or indifference? A qualitative study of patient decisions about recruitment to an epilepsy treatment trial.

Authors:  Krysia Canvin; Ann Jacoby
Journal:  Trials       Date:  2006-12-12       Impact factor: 2.279

View more
  6 in total

1.  An aqueous extract of Khaya senegalensis (Desv.) A. Juss. (Meliaceae) prevents seizures and reduces anxiety in kainate-treated rats: modulation of GABA neurotransmission, oxidative stress, and neuronal loss in the hippocampus.

Authors:  Antoine Kavaye Kandeda; Stéphanie Lewale; Etienne Djeuzong; J Kouamouo; Théophile Dimo
Journal:  Heliyon       Date:  2022-05-26

2.  Examining brief and ultra-brief anxiety and depression screening methods in a real-world epilepsy clinic sample.

Authors:  Heidi M Munger Clary; Mingyu Wan; Kelly Conner; Gretchen A Brenes; James Kimball; Esther Kim; Pamela Duncan; Beverly M Snively
Journal:  Epilepsy Behav       Date:  2021-04-08       Impact factor: 2.937

3.  Reply to Braillon.

Authors:  Heidi M Munger Clary; James Kimball; Gretchen Brenes; Cormac O'Donovan; Beverly M Snively; Pamela Duncan
Journal:  Epilepsy Behav       Date:  2020-04-04       Impact factor: 3.337

Review 4.  Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.

Authors:  Adam Strzelczyk; Susanne Schubert-Bast
Journal:  CNS Drugs       Date:  2022-10-04       Impact factor: 6.497

5.  Patient-reported outcomes via electronic health record portal versus telephone: a pragmatic randomized pilot trial of anxiety or depression symptoms in epilepsy.

Authors:  Heidi M Munger Clary; Beverly M Snively; Umit Topaloglu; Pamela Duncan; James Kimball; Halley Alexander; Gretchen A Brenes
Journal:  JAMIA Open       Date:  2022-10-12

6.  Neurologist prescribing versus psychiatry referral: Examining patient preferences for anxiety and depression management in a symptomatic epilepsy clinic sample.

Authors:  Heidi M Munger Clary; Rachel D Croxton; Beverly M Snively; Gretchen A Brenes; James Lovato; Fatemeh Sadeghifar; James Kimball; Cormac O'Donovan; Kelly Conner; Esther Kim; Jonathan Allan; Pamela Duncan
Journal:  Epilepsy Behav       Date:  2020-11-24       Impact factor: 2.937

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.